COMPASS IS DRUGGING THE IMMUNE SYNAPSE TO TREAT HUMAN DISEASE

Our central belief is that the complexity of the immune system requires a methodical scientific approach to identify and drug key pathways. Using our proprietary antibody discovery and screening technologies, we have identified methods to unlock novel biology of the immune synapse, and have created therapeutic candidates leveraging these insights. Our commitment is to build the world’s leading biopharmaceutical company that is comprehensively drugging the human immune system.
WE ARE BUILDING A UNIQUE PIPELINE
While conventional drug discovery aims at blockade or activation of discrete targets, we have taken a different approach, studying several agonists and antagonists simultaneously in a comprehensive manner. Applying this approach, we have created a portfolio of next generation immunomodulatory biologic drug candidates, drug combinations, and multispecifics to treat cancer, autoimmune disorders, and other diseases.

WE CREATE VALUE THROUGH GREAT SCIENCE

Our team has passion for great science and shares our philosophy of building value for patients and investors through our therapeutic pipeline. Since our founding in 2014, Compass has closed $83M in Series A financing and has up to $110M in additional investment commitments that are available to fund our ambitious plan to build a leading biopharmaceutical company from the ground up.